Blood-Based T-Cell Diagnosis of Celiac Disease

The blood-based T-cell diagnosis of celiac disease (CeD) represents a groundbreaking advancement in the diagnostic landscape, particularly for individuals adhering to a gluten-free diet (GFD). The study introduces and validates the whole-blood interleukin-2 (IL-2) release assay (WBAIL-2) as a novel diagnostic tool, addressing the limitations of traditional serology and intestinal biopsy methods.

### Key Highlights of Blood-Based T-Cell Diagnosis for CeD:

#### 1. **Study Objective**:

• The WBAIL-2 assay was developed to detect gluten-specific CD4⁺ T cells by measuring IL-2 release after gluten peptide stimulation in blood samples.
• This approach is particularly useful for diagnosing CeD in patients already on a GFD, where conventional diagnostics often fail due to normalized serology or lack of active symptoms.

#### 2. **Clinical Challenge**:

• Traditional diagnostic methods for CeD, such as serological tests and intestinal biopsy, require active gluten consumption, posing challenges for patients who have adopted a GFD to manage symptoms.
• These methods are invasive, time-consuming, and may not yield reliable results for GFD patients.

#### 3. **Novel Diagnostic Approach**:

• WBAIL-2 provides a non-invasive, blood-based alternative that bypasses the need for gluten consumption.
• The assay measures IL-2 secretion from gluten-specific CD4⁺ T cells, offering a practical and simpler workflow compared to complex T-cell assays or biopsy procedures.

#### 4. **Study Design**:

• The validation study involved 181 adults, including:
• 88 patients with CeD (75 on GFD and 13 with active disease),
• 32 individuals with nonceliac gluten sensitivity (NCGS),
• 61 healthy controls.
• This diverse cohort allowed robust assessment of the assay’s diagnostic performance.

#### 5. **High Diagnostic Accuracy**:

• In HLA-DQ2.5⁺ patients, WBAIL-2 demonstrated:
• **90% sensitivity** and **95% specificity** for CeD.
• The assay performed comparably to HLA-tetramer-based methods but with a simpler and more accessible workflow.

#### 6. **Correlation With T-Cell Activity**:

• WBAIL-2 results strongly correlated with tetramer-positive gluten-specific T-cell frequency and serum IL-2 levels after gluten challenge, confirming its biological relevance.
• Higher WBAIL-2 and serum IL-2 levels also predicted more severe gluten-induced symptoms, such as vomiting, making it a potential biomarker for clinical response.

#### 7. **Performance in GFD Patients**:

• A significant advantage of WBAIL-2 is its ability to accurately identify CeD even in patients strictly adhering to a GFD, unlike serology tests that often normalize with gluten withdrawal.

#### 8. **Mechanistic Validation**:

• Cytokine capture assays confirmed that IL-2 secretion originates directly from gluten-specific CD4⁺ T cells, validating the assay’s mechanistic basis as a disease marker.

#### 9. **In Vivo–In Vitro Correlation**:

• A strong correlation was observed between serum IL-2 levels after gluten ingestion (GCIL-2) and WBAIL-2 values, indicating complementary diagnostic potential.

#### 10. **Dynamic Response to Gluten Exposure**:

• After a gluten challenge, WBAIL-2 values increased up to 30-fold, mirroring the expansion of circulating gluten-reactive T-effector memory cells.

#### 11. **HLA Genotype Influence**:

• The assay’s sensitivity was genotype-specific, with lower sensitivity (56%) observed in HLA-DQ8⁺ patients compared to HLA-DQ2.5⁺ individuals.

#### 12. **First-Degree Relatives**:

• Some first-degree relatives of CeD patients showed positive WBAIL-2 results despite negative serology, suggesting subclinical immune activation or genetic predisposition toward CeD.

#### 13. **Comparison With Cytokine Markers**:

• IL-2 emerged as the strongest diagnostic biomarker among cytokines tested, outperforming IFN-γ and IL-17A in specificity.

#### 14. **Variability and Precision**:

• The WBAIL-2 assay demonstrated acceptable variability (18–46% coefficient of variation), comparable to other widely used immune assays like QuantiFERON-Gold for tuberculosis.

#### 15. **No Effect of Autoimmunity**:

• IL-2 responses were unaffected by the presence of other autoimmune diseases in CeD patients, confirming the assay’s specificity to gluten-reactive T-cell activation.

#### 16. **Clinical Applicability**:

• WBAIL-2 requires only 4 mL of blood and simple laboratory equipment, making it feasible for routine use in clinical settings without specialized immunology infrastructure.

#### 17. **Advantages Over Tetramer Assays**:

• Unlike tetramer-based methods, WBAIL-2 does not require knowledge of patient HLA type or large blood volumes, making it more practical for widespread diagnostic use.

#### 18. **Future Potential**:

• The assay could serve as a biopsy-free diagnostic tool for CeD and may also be used to monitor disease activity or assess treatment response in CeD and other T-cell–mediated conditions.

#### 19. **Translational Implications**:

• WBAIL-2 and serum IL-2 assays represent a shift toward immune-based, non-invasive diagnosis for CeD, offering a practical, rapid, and patient-friendly alternative to traditional biopsy-dependent methods.

### Conclusion:

The WBAIL-2 assay marks a significant advancement in diagnosing celiac disease, providing a sensitive, specific, and non-invasive alternative to traditional methods. It is particularly beneficial for patients on a gluten-free diet, offering accurate results without requiring gluten consumption. With its simple workflow and minimal blood volume requirements, WBAIL-2 has the potential to become a routine diagnostic tool, paving the way for more accessible and patient-centered care in celiac disease management.